Restoring Immune Function in Critical Care
Acquired immune deficiency in critically ill patients
Our groundbreaking therapeutic approach is specifically designed to treat acquired immune deficiency in critically ill patients. By restoring immune function and immune homeostasis, we address a critical gap in intensive care medicine.
Addressing an Unmet Medical Need
Immunosuppression in critically ill patients leads to devastating outcomes: higher death rates and lasting health problems.
ICU patients, and in particular sepsis patients, endure both sustained excessive inflammation and immune suppression, resulting in a failure to return to normal homeostasis. Immunoparalysis compromises the patient’s ability to combat invading pathogens and is associated with high mortality rates, prolonged ICU stay, long-term impairments, and significant healthcare costs.
First-in-Class Potential
The interplay between hyperinflammation and immunosuppressive processes is complex and evolves over time. A prolonged immune boosting may stimulate hyperinflammation and may eventually magnify immune exhaustion.
Combioxin’s groundbreaking approach is being developed as a new class of targeted, disease-modifying, add-on treatment to existing standard of care. It has the potential to act rapidly to restore immune homeostasis.
.